A model was developed from which the cost-effectiveness of prevaccination serologic screening for measles could be estimated, for any combination of antibody screening costs and prevalence of antibody to measles.
This model was tested using sera obtained prospectively from 222 health care workers, including 181 born in or after 1957 who had no history of measles, no measles vaccine after 1980, and no documentation of immunity to measles.
Mots-clés Pascal : Virose, Infection, Amérique du Nord, Amérique, Vaccination, Rougeole, Dépistage, Anticorps, Sérum, Analyse coût efficacité, Prévalence, Personnel sanitaire, Hôpital, Immunité humorale, Economie santé, Epidémiologie, Homme, Etats Unis, Prévaccinal
Mots-clés Pascal anglais : Viral disease, Infection, North America, America, Vaccination, Measles, Screening, Antibody, Serum, Cost efficiency analysis, Prevalence, Health staff, Hospital, Humoral immunity, Health economy, Epidemiology, Human, United States
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 91-0532453
Code Inist : 002B05A02. Création : 199406.